Dicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offer

Douglas Fambrough, co-founder and current CEO of Dicerna, which recently received a USD 3.3bn acquisition offer by Novo Nordisk, no longer intends to offer his own shares as a part of the deal, fearing an insider trading crackdown.
Photo: POOL New/REUTERS / X80003
Photo: POOL New/REUTERS / X80003
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

Novo Nordisk's cash tender offer to acquire all outstanding Dicerna shares no longer includes CEO Douglas Fambrough's personal shares, according to documents amending the original filing to the US Securities and Exchange Commission (SEC).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading